Donga Pharmaceutical’s Orthomol Tops Domestic Multivitamin Market for Three Consecutive Years

The premium multivitamin "Orthomol" has ranked number one in sales in the domestic multivitamin market for three consecutive years.

Donga Pharmaceutical announced on March 31 that, according to a study by the global research firm Euromonitor International, Orthomol has maintained the top sales position in both the online and offline multivitamin markets in Korea for three consecutive years, from 2023 through last year.

Donga Pharmaceutical Multivitamin "Orthomol". Donga Pharmaceutical

This survey measured sales figures based on the total sales amount of multivitamins across all distribution channels, including over-the-counter pharmaceuticals in both online and offline markets.

Donga Pharmaceutical, the official domestic partner of Orthomol, entered the Korean market in 2020 with the launch of its flagship product "Immune." In 2023, the company expanded its product portfolio by introducing all-in-one multivitamins "VitalM" and "VitalF," designed to address individual health concerns.

The Immune line is formulated with vitamins B, C, E, niacin, and zinc to help maintain normal immune function, while the Vital line supports daily vitality by providing up to 23 types of micronutrients, including omega-3.

From a distribution perspective, the company has enhanced its competitiveness across all channels by increasing consumer accessibility through various touchpoints, including H&B stores, department stores, mobile commerce, and online shopping malls.

In particular, Orthomol has set itself apart by proposing a new consumer value as a "premium health gift," going beyond function-focused products. The innovative dual-formulation, which combines liquid and tablets, offers a unique consumption experience and has established a distinctive position in the multivitamin market.

As the multivitamin market changes rapidly, consumer selection criteria are also evolving toward balanced nutritional design and systematic product composition tailored to individual lifestyles. In line with this trend, Orthomol has continued to maintain a stable market presence based on brand reliability and product competitiveness.

A representative from Donga Pharmaceutical’s Orthomol division stated, "Orthomol officially distributed in Korea retains the research standards of the German headquarters, while also applying formulations that consider the nutritional intake characteristics of Koreans. This year, we will further strengthen brand competitiveness and create new growth opportunities by expanding our range of formulations and product lines."

Meanwhile, Donga Pharmaceutical continues to strive to provide healthcare solutions for consumers, upholding its founding philosophy that "every product we create must contribute to the health of the nation."

This content was produced with the assistance of AI translation services.